Breast cancer surveillance for epithelial ovarian cancer patients with BRCA1 and BRCA2 pathogenic variants: a single-center retrospective study
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Junko Hasegawa-Minato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, BRCA2 Protein, BRCA1 Protein, Ovarian Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: JSPS KAKENHI.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To identify a method for breast cancer (BC) surveillance in patients with epithelial ovarian cancer (EOC) with germline BRCA1/2 pathogenic variants (gBRCA1/2m) and the incidence of BC after EOC in the era of broad PARP inhibitors use.
Methods
We retrospectively analyzed the data on EOC patients who had gBRCA1/2m by genetic testing between January 2017 and August 2023 in our single center.
Results
Of 125 patients with EOC, 33 had gBRCA1/2m. Of these, 27 (81.8%) underwent BC surveillance, 20 ultrasound and/or mammography, and seven magnetic resonance imaging (MRI). The median time from EOC diagnosis to the initiation of BC surveillance was 8 months. EOC recurrence was significantly lower in the group with MRI than in the group without MRI (no case vs. 10 cases, P = .0261). The duration from EOC diagnosis to the start of BC surveillance was longer in the group with MRI than in the group without MRI (21 vs. 7 months, P = .1033). Two (6.1%) patients developed BC after EOC. Both cases were early stage, triple-negative BCs that occurred more than 3 years after the diagnosis of stage III EOC.
Conclusions
With the advent of PARP inhibitors, long-term survival is expected to increase, and a certain number of patients with EOC after initial treatment may benefit from BC surveillance using MRI. In particular, BC surveillance with MRI may be considered for patients who have not experienced EOC recurrence for more than 2 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
- Division of Obstetrics and Gynecology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 4 Chome-4-1 Komatsushima, Aoba-ku, Sendai, Miyagi 981-8558, Japan.
- Department of Clinical Biobank, Tohoku University Advanced Research Center for Innovations in Next-Generation Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8573, Japan.
ORCID-Profile: Junko Hasegawa-Minato, Shogo Shigeta, Muneaki Shimada
Förderung
- JSPS KAKENHI
Zitieren
APA
Hasegawa-Minato, J., Tochigi, M., Miyahara, S., Kudo, K., Shibuya, Y., Hashimoto, C., Ishibashi, M., Shigeta, S., Tokunaga, H., & Shimada, M. (2025). Breast cancer surveillance for epithelial ovarian cancer patients with BRCA1 and BRCA2 pathogenic variants: a single-center retrospective study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf010
Vancouver
Hasegawa-Minato J, Tochigi M, Miyahara S, Kudo K, Shibuya Y, Hashimoto C, et al. Breast cancer surveillance for epithelial ovarian cancer patients with BRCA1 and BRCA2 pathogenic variants: a single-center retrospective study. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf010
BibTeX
@article{HasegawaMinato2025,
author = {Hasegawa-Minato, Junko and Tochigi, Mikako and Miyahara, Shuko and Kudo, Kei and Shibuya, Yusuke and Hashimoto, Chiaki and Ishibashi, Masumi and Shigeta, Shogo and Tokunaga, Hideki and Shimada, Muneaki},
title = {Breast cancer surveillance for epithelial ovarian cancer patients with BRCA1 and BRCA2 pathogenic variants: a single-center retrospective study},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf010}
}
EUVIMED